This week in drug discovery (7-11 Oct)
News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer.
The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1 agonists and an advanced theory of bipolar disorder.
If these are of interest, don’t forget to register for DDW’s Neuroscience Showcase on 24 October.
The top stories:
CRISPR gene editing reduces brain function decline with age
A new study has revealed that reducing the activity of a particular gene using CRISPR gene editing can rejuvenate stem cells in the brain to create fresh neurons.
News from SfN’s Neuroscience 2024: The brain on GLP-1 agonists
Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024.
Neuroscience 2024: Leveraging human stem cells to treat diseases
Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases.
Breakthroughs in bipolar disorder announced at Neuroscience 2024
A Walsh Research Institute scientist presented an advanced theory of bipolar disorder at the annual meeting of the Society for Neuroscience, Neuroscience 2024.
Physics Nobel prize awarded for machine learning inventions
The Princeton Neuroscience Institute’s John Hopfield has been awarded the Novel Prize in physics for foundational discoveries and inventions that enable machine learning with artificial neural networks.